Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable
Depomed (NYSE:ASRT) Frequently Asked Questions
What is Depomed's stock symbol?
Depomed trades on the New York Stock Exchange (NYSE) under the ticker symbol "ASRT."
How were Depomed's earnings last quarter?
Depomed, Inc. (NYSE:ASRT) released its quarterly earnings data on Wednesday, March, 6th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.20 by $0.10. The company had revenue of $62.80 million for the quarter, compared to the consensus estimate of $60.94 million. Depomed's revenue for the quarter was down 33.5% compared to the same quarter last year. During the same period last year, the company earned $0.15 EPS. View Depomed's Earnings History.
When is Depomed's next earnings date?
What price target have analysts set for ASRT?
1 equities research analysts have issued 1-year price objectives for Depomed's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Depomed's stock price to reach $3.00 in the next year. This suggests a possible upside of 123.9% from the stock's current price. View Analyst Price Targets for Depomed.
What is the consensus analysts' recommendation for Depomed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Depomed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Depomed.
Has Depomed been receiving favorable news coverage?
Headlines about ASRT stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Depomed earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Depomed.
Who are some of Depomed's key competitors?
Some companies that are related to Depomed include HEXO (HEXO), Next Science (NXS), Benchmark (BMK), ICC Labs (ICC), Amryt Pharma (AMYT), Shield Therapeutics (STX), Green Organic Dutchman (TGOD), Probiotec (PBP), CannTrust (TRST), ESSA Pharma (EPI), Supreme Cannabis (FIRE), WeedMD (WMD), Auscann Group (AC8), Flowr (FLWR) and Delta 9 Cannabis (NINE).
What other stocks do shareholders of Depomed own?
Who are Depomed's key executives?
Depomed's management team includes the folowing people:
- Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
- Mr. Phillip B. Donenberg, CFO & Sr. VP (Age 57)
- Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
- Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)
- Mr. John B. Thomas, Sr. VP of IR & Corp. Communications (Age 54)
How do I buy shares of Depomed?
Shares of ASRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Depomed's stock price today?
One share of ASRT stock can currently be purchased for approximately $1.34.
How big of a company is Depomed?
What is Depomed's official website?
MarketBeat Community Rating for Depomed (NYSE ASRT)
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe ASRT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASRT will underperform the S&P 500 over the long term. You may vote once every thirty days.
